PT  - JOURNAL ARTICLE
AU  - B S Tsai
AU  - R H Keith
AU  - D Villani-Price
AU  - J F Kachur
AU  - D C Yang
AU  - S W Djuric
AU  - S Yu
TI  - The in vitro pharmacology of SC-51146: a potent antagonist of leukotriene B4 receptors.
DP  - 1994 Mar 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 1499--1505
VI  - 268
IP  - 3
4099  - http://jpet.aspetjournals.org/content/268/3/1499.short
4100  - http://jpet.aspetjournals.org/content/268/3/1499.full
SO  - J Pharmacol Exp Ther1994 Mar 01; 268
AB  - Previously, we reported that SC-41930 is a potent leukotriene B4 (LTB4) receptor antagonist. An analog of SC-41930, SC-51146, was evaluated as an antagonist of LTB4 receptors. SC-51146 was shown to bind to LTB4 high affinity binding sites on human neutrophils (PMN) with a dissociation constant (KD) value of 1.5 +/- 0.1 nM, compared to 19 +/- 1.3 nM for SC-41930. PMN chemotaxis studies and Scatchard analyses of [3H]LTB4 binding in PMN membranes indicated that SC-51146 acted as a competitive antagonist. The IC50 value of SC-51146 for the inhibition of PMN chemotaxis induced by 30 nM LTB4 was 38 +/- 12 nM. SC-51146 inhibited PMN degranulation induced by 50 nM LTB4 with an IC50 value of 29 +/- 7 nM. The antagonism by SC-51146 of LTB4-induced PMN degranulation appeared to be noncompetitive. The specificity of SC-51146 for LTB4 receptors vs. fMLP receptors was improved approximately 29 and 44 times over SC-41930. SC-51146 showed relatively weak inhibitory activity on the production of superoxide, LTB4 and/or prostaglandin E2 by human PMN or HL-60 cells. SC-51146 had little activity on ram seminal vesicle cyclooxygenase, and no activity on porcine pancreatic phospholipase A2. SC-51146 is a racemate comprised of the (+) enantiomer, SC-53228, and the (-) enantiomer, SC-53229. Both stereoisomers exhibited pharmacological profiles similar to SC-51146 in these aforementioned in vitro systems. The highly potent and specific antagonistic action of SC-51146 on LTB4 receptors should be particularly useful in elucidating the role of LTB4 in the pathogenesis of inflammatory diseases where excessive levels of LTB4 have been reported.